World Journal of Surgery

, Volume 37, Issue 7, pp 1688–1694 | Cite as

Notch1 Contributes to Chemoresistance to Gemcitabine and Serves as an Unfavorable Prognostic Indicator in Pancreatic Cancer

  • Xiao Du
  • Yu-Pei ZhaoEmail author
  • Tai-Ping Zhang
  • Li Zhou
  • Ge Chen
  • Quan-Cai Cui
  • Jie Shi
  • Tian-Xiao Wang
  • Lei You
  • Hong Shu



Pancreatic cancer (PC) carries frequent chemoresistance and extremely dismal prognosis. The underlying mechanisms remain to be further elucidated. We here report the role of Notch1 in gemcitabine resistance and its prognostic significance in PC.


A small interfering RNA (siRNA) specifically targeting Notch1 was transiently transfected into three PC cell lines (AsPC-1, BxPC-3, and MIA PaCa-2), followed by examination of chemosensitivity to gemcitabine. On the other hand, Notch1 expression was evaluated immunohistochemically and correlated with clinicopathological and prognostic variables.


Successful knockdown of Notch1 by specific siRNA induced increased chemosensitivity to gemcitabine in all three cell lines. Immunohistochemical staining revealed that Notch1 was highly expressed in PC tissues (54.8 %), in contrast to that in para-tumor tissues (16.4 %). In addition, Notch1 positivity was significantly correlated with early-term metastasis and shortened overall survival. Multivariate Cox regression identified Notch1 as an independent prognostic factor.


Notch1 contributes to chemoresistance to gemcitabine, and serves as a significant indicator of unfavorable prognosis in PC.


Overall Survival Pancreatic Cancer Gemcitabine Pancreatic Cancer Cell Notch Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

268_2013_2010_MOESM1_ESM.tif (208 kb)
Fig. S1 Impacts of Notch1 siRNA on growth inhibition in 3 cell lines. Supplementary material 1 (TIFF 208 kb)


  1. 1.
    Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRefGoogle Scholar
  2. 2.
    Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267PubMedCrossRefGoogle Scholar
  3. 3.
    Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617PubMedCrossRefGoogle Scholar
  4. 4.
    Shrikhande SV, Kleeff J, Reiser C et al (2007) Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 14:118–127PubMedCrossRefGoogle Scholar
  5. 5.
    Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  6. 6.
    Xie DR, Yang Q, Chen DL et al (2010) Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol 40:432–441PubMedCrossRefGoogle Scholar
  7. 7.
    Tien AC, Rajan A, Bellen HJ (2009) A Notch updated. J Cell Biol 184:621–629PubMedCrossRefGoogle Scholar
  8. 8.
    Ranganathan P, Weaver KL, Capobianco AJ (2011) Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11:338–351PubMedCrossRefGoogle Scholar
  9. 9.
    Takebe N, Harris PJ, Warren RQ et al (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97–106PubMedCrossRefGoogle Scholar
  10. 10.
    Miyamoto Y, Maitra A, Ghosh B et al (2003) Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3:565–576PubMedCrossRefGoogle Scholar
  11. 11.
    Buchler P, Gazdhar A, Schubert M et al (2005) The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg 242:791–800PubMedCrossRefGoogle Scholar
  12. 12.
    Wang Z, Banerjee S, Li Y et al (2006) Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 66:2778–2784PubMedCrossRefGoogle Scholar
  13. 13.
    Wang Z, Zhang Y, Li Y et al (2006) Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5:483–493PubMedCrossRefGoogle Scholar
  14. 14.
    Kimura K, Satoh K, Kanno A et al (2007) Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci 98:155–162PubMedCrossRefGoogle Scholar
  15. 15.
    De La OJ, Emerson LL, Goodman JL et al (2008) Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A 105:18907–18912CrossRefGoogle Scholar
  16. 16.
    Mullendore ME, Koorstra JB, Li YM et al (2009) Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 15:2291–2301PubMedCrossRefGoogle Scholar
  17. 17.
    Ristorcelli E, Beraud E, Mathieu S et al (2009) Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. Int J Cancer 125:1016–1026PubMedCrossRefGoogle Scholar
  18. 18.
    Bao B, Wang Z, Ali S et al (2011) Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 307:26–36PubMedCrossRefGoogle Scholar
  19. 19.
    Hanlon L, Avila JL, Demarest RM et al (2010) Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res 70:4280–4286PubMedCrossRefGoogle Scholar
  20. 20.
    Mazur PK, Einwachter H, Lee M et al (2010) Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 107:13438–13443PubMedCrossRefGoogle Scholar
  21. 21.
    Vizio B, Mauri FA, Prati A et al (2012) Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma. Oncol Rep 27:69–76PubMedGoogle Scholar
  22. 22.
    Cheung HC, Corley LJ, Fuller GN et al (2006) Polypyrimidine tract binding protein and Notch1 are independently re-expressed in glioma. Mod Pathol 19:1034–1041PubMedGoogle Scholar
  23. 23.
    Murtaugh LC, Stanger BZ, Kwan KM et al (2003) Notch signaling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci U S A 100:14920–14925PubMedCrossRefGoogle Scholar
  24. 24.
    Yao J, Qian C (2009) Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3 K/Akt-dependent pathway. Med Oncol 27:1017–1022PubMedCrossRefGoogle Scholar
  25. 25.
    Ansari D, Rosendahl A, Elebro J et al (2011) Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg 98:1041–1055PubMedCrossRefGoogle Scholar
  26. 26.
    Chu D, Zhang Z, Zhou Y et al (2011) Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol 22:2440–2447PubMedCrossRefGoogle Scholar
  27. 27.
    Reedijk M, Odorcic S, Chang L et al (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65:8530–8537PubMedCrossRefGoogle Scholar
  28. 28.
    Donnem T, Andersen S, Al-Shibli K et al (2010) Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer 116:5676–5685PubMedCrossRefGoogle Scholar
  29. 29.
    Chang HH, Lee H, Hu MK et al (2010) Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin Cancer Res 16:4411–4420PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2013

Authors and Affiliations

  • Xiao Du
    • 1
  • Yu-Pei Zhao
    • 1
    Email author
  • Tai-Ping Zhang
    • 1
  • Li Zhou
    • 1
  • Ge Chen
    • 1
  • Quan-Cai Cui
    • 2
  • Jie Shi
    • 2
  • Tian-Xiao Wang
    • 1
  • Lei You
    • 1
  • Hong Shu
    • 1
  1. 1.Department of General SurgeryPeking Union Medical College Hospital, National Laboratory of Medical Molecular Biology, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.Department of PathologyPeking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations